Therapeutic potential of CDK inhibitors in MLL leukemias

被引：1
|
作者：
Frame, Sheelagh
Hogben, Morag
Munro, Clare
Blake, David G.
Green, Simon R.
Zheleva, Danielle I.
机构：
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/1538-7445.AM10-3886
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3886
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Therapeutic potential of CDK11 in cancer
    Blazek, Dalibor
    CLINICAL AND TRANSLATIONAL MEDICINE, 2023, 13 (03):
  • [32] Models of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing
    Zapatero-Solana, Elisabet
    Ding, Yan
    Pulliam, Nicholas
    de Dios, Alfonso
    Ortiz-Ruiz, Maria Jesus
    Lallena, Maria Jose
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (06)
  • [33] New insights to the MLL recombinome of acute leukemias
    C Meyer
    E Kowarz
    J Hofmann
    A Renneville
    J Zuna
    J Trka
    R Ben Abdelali
    E Macintyre
    E De Braekeleer
    M De Braekeleer
    E Delabesse
    M P de Oliveira
    H Cavé
    E Clappier
    J J M van Dongen
    B V Balgobind
    M M van den Heuvel-Eibrink
    H B Beverloo
    R Panzer-Grümayer
    A Teigler-Schlegel
    J Harbott
    E Kjeldsen
    S Schnittger
    U Koehl
    B Gruhn
    O Heidenreich
    L C Chan
    S F Yip
    M Krzywinski
    C Eckert
    A Möricke
    M Schrappe
    C N Alonso
    B W Schäfer
    J Krauter
    D A Lee
    U zur Stadt
    G Te Kronnie
    R Sutton
    S Izraeli
    L Trakhtenbrot
    L Lo Nigro
    G Tsaur
    L Fechina
    T Szczepanski
    S Strehl
    D Ilencikova
    M Molkentin
    T Burmeister
    T Dingermann
    Leukemia, 2009, 23 : 1490 - 1499
  • [34] Molecular pathogenesis of MLL-associated leukemias
    Eguchi, M
    Eguchi-Ishimae, M
    Greaves, M
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2005, 82 (01) : 9 - 20
  • [35] Molecular Pathogenesis of MLL-Associated Leukemias
    Mariko Eguchi
    Minenori Eguchi-Ishimae
    Mel Greaves
    International Journal of Hematology, 2005, 82 : 9 - 20
  • [36] New insights to the MLL recombinome of acute leukemias
    Meyer, C.
    Kowarz, E.
    Hofmann, J.
    Renneville, A.
    Zuna, J.
    Trka, J.
    Ben Abdelali, R.
    Macintyre, E.
    De Braekeleer, E.
    De Braekeleer, M.
    Delabesse, E.
    de Oliveira, M. P.
    Cave, H.
    Clappier, E.
    van Dongen, J. J. M.
    Balgobind, B. V.
    van den Heuvel-Eibrink, M. M.
    Beverloo, H. B.
    Panzer-Gruemayer, R.
    Teigler-Schlegel, A.
    Harbott, J.
    Kjeldsen, E.
    Schnittger, S.
    Koehl, U.
    Gruhn, B.
    Heidenreich, O.
    Chan, L. C.
    Yip, S. F.
    Krzywinski, M.
    Eckert, C.
    Moericke, A.
    Schrappe, M.
    Alonso, C. N.
    Schaefer, B. W.
    Krauter, J.
    Lee, D. A.
    zur Stadt, U.
    Kronnie, G. Te
    Sutton, R.
    Izraeli, S.
    Trakhtenbrot, L.
    Lo Nigro, L.
    Tsaur, G.
    Fechina, L.
    Szczepanski, T.
    Strehl, S.
    Ilencikova, D.
    Molkentin, M.
    Burmeister, T.
    Dingermann, T.
    LEUKEMIA, 2009, 23 (08) : 1490 - 1499
  • [37] MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs
    Maifrede, Silvia
    Martinez, Esteban
    Nieborowska-Skorska, Margaret
    Di Marcantonio, Daniela
    Hulse, Michael
    Le, Bac Viet
    Zhao, Huaqing
    Piwocka, Katarzyna
    Tempera, Italo
    Sykes, Stephen M.
    Skorski, Tomasz
    BLOOD ADVANCES, 2017, 1 (19) : 1467 - 1472
  • [38] More complexity in MLL-associated leukemias
    Humphries, K
    BLOOD, 2004, 103 (05) : 1566 - 1567
  • [39] Investigation of the influence of different MLL breakpoints on the development of MLL-rearranged leukemias
    Fitzel, R.
    Bruestl, S.
    Korkmaz, F.
    Mankel, B.
    Erkner, E.
    Keppeler, H.
    Lengerke, C.
    Schneidawind, D.
    Schneidawind, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 92 - 92
  • [40] Potential role for wild-type p53 in leukemias with MLL gene translocations
    Megonigal, MD
    Rappaport, EF
    Nowell, PC
    Lange, BJ
    Felix, CA
    ONCOGENE, 1998, 16 (10) : 1351 - 1356
12345